---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-054312"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:44:50.508060+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences Q4 revenue up 21% to $58.6M; full year net loss $11.3M; guides 5-10% growth for 2024

## Summary
- Total revenue Q4 $58.6M (+21% YoY); organic $48.8M (+1%); full year $193.4M (+18%).
- Q4 net income $6.3M vs $3.7M; full year net loss $11.3M vs income $2.5M.
- 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income.
- Repurchased 5.3M shares for $34.7M in Q4; 6.6M total since May 2023.
- Introduced Cytek Orion automated antibody cocktail prep system.

## SEC filing metadata
- accession: 0001193125-24-054312
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/0001193125-24-054312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/d781057d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-054312
- JSON: https://secwatch.observer/filing/0001193125-24-054312.json
- Plain text: https://secwatch.observer/filing/0001193125-24-054312.txt

## Key facts
- Earnings Releases
  Cytek Biosciences, Inc. reported year ended December 31, 2023 results: revenue $193.4 million, net income $11.3 million.
  - Period: year ended December 31, 2023
  - Revenue: $193.4 million
  - Net income: $11.3 million
  - Result: reported results
  source text: the fourth quarter of 2022. Fourth quarter revenue from the product lines acquired from Luminex Corporation (“Luminex”) on February 28, 2023 was $9.8 million • Total revenue was $193.4 million, or $194.1 million on a non-GAAP constant currency basis, for the full year 2023, representing 18% and 13% increases, respectively, over the full year 2022. • Organic revenue was
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/0001193125-24-054312-index.htm
- Earnings Releases
  Cytek Biosciences, Inc. reported fourth quarter ended December 31, 2023 results: revenue $58.6 million, net income $6.3 million.
  - Period: fourth quarter ended December 31, 2023
  - Revenue: $58.6 million
  - Net income: $6.3 million
  - Result: reported results
  source text: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlights • Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period of 2022 •
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312524054312/0001193125-24-054312-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.